Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia
about
Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity.Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cellsNon ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.
P2860
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Combining the ABL1 kinase inhi ...... for BCR-ABL-positive leukemia
@ast
Combining the ABL1 kinase inhi ...... for BCR-ABL-positive leukemia
@en
type
label
Combining the ABL1 kinase inhi ...... for BCR-ABL-positive leukemia
@ast
Combining the ABL1 kinase inhi ...... for BCR-ABL-positive leukemia
@en
prefLabel
Combining the ABL1 kinase inhi ...... for BCR-ABL-positive leukemia
@ast
Combining the ABL1 kinase inhi ...... for BCR-ABL-positive leukemia
@en
P2093
P2860
P1433
P1476
Combining the ABL1 kinase inhi ...... for BCR-ABL-positive leukemia
@en
P2093
Seiichi Okabe
Shinya Kimura
Taira Maekawa
Tetsuzo Tauchi
Toshihiko Kitahara
Yoko Tanaka
P2860
P304
P356
10.1371/JOURNAL.PONE.0089080
P407
P577
2014-02-28T00:00:00Z